These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7112515)

  • 1. Are synthetic inhibitors able to improve factor Xa assays using peptide substrates?
    Stürzebecher J; Markwardt F; Wagner G; Voigt B
    Thromb Res; 1982 May; 26(3):221-6. PubMed ID: 7112515
    [No Abstract]   [Full Text] [Related]  

  • 2. Differentiation of thrombin- and factor Xa-related amidolytic activity in plasma by means of a synthetic thrombin inhibitor.
    Svendsen L; Brogli M; Lindeberg G; Stocker K
    Thromb Res; 1984 Jun; 34(5):457-62. PubMed ID: 6377574
    [No Abstract]   [Full Text] [Related]  

  • 3. [Simultaneous determination of zymogen activation time and zymogen level using chromogenic substrates in blood coagulation analysis].
    Svendsen L; Brogli M; Stocker K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):150-6. PubMed ID: 6177596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
    Chmielewska J; Latallo ZS
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of synthetic inhibitors in coagulation physiological tests with peptide substrates].
    Stürzebecher J; Klessen C
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):157-60. PubMed ID: 6177597
    [No Abstract]   [Full Text] [Related]  

  • 6. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates.
    Lottenberg R; Christensen U; Jackson CM; Coleman PL
    Methods Enzymol; 1981; 80 Pt C():341-61. PubMed ID: 6210826
    [No Abstract]   [Full Text] [Related]  

  • 7. New chromogenic substrates for thrombin with increased specificity.
    Kolde HJ; Eberle R; Heber H; Heimburger N
    Thromb Haemost; 1986 Oct; 56(2):155-9. PubMed ID: 2949389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chromogenic substrates for determining coagulation factor X and their use in clinical practice (review of the literature)].
    Bol'shakova TD; Iakunin GA; Smolianitskiĭ AIa
    Lab Delo; 1985; (11):643-8. PubMed ID: 2417012
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthetic inhibitors of bovine factor Xa and thrombin comparison of their anticoagulant efficiency.
    Stürzebecher J; Stürzebecher U; Vieweg H; Wagner G; Hauptmann J; Markwardt F
    Thromb Res; 1989 May; 54(3):245-52. PubMed ID: 2749616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of factor X and heparin with chromogenic substrate.
    Aiach M; Michaud A; Capron L; Fiessinger JN
    Acta Chir Scand Suppl; 1982; 509():109-13. PubMed ID: 6962612
    [No Abstract]   [Full Text] [Related]  

  • 11. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?
    Stürzebecher J; Stürzebecher U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):152-6. PubMed ID: 2459011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human coagulation factor Xa by thrombin substrates.
    Orthner CL; Morris S; Kosow DP
    Thromb Res; 1981 Sep; 23(6):533-9. PubMed ID: 7324010
    [No Abstract]   [Full Text] [Related]  

  • 13. Automated instrumentation and the laboratory diagnosis of bleeding and thrombotic disorders.
    Walenga J; Fareed J; Bermes EW
    Semin Thromb Hemost; 1983 Jul; 9(3):172-93. PubMed ID: 6351253
    [No Abstract]   [Full Text] [Related]  

  • 14. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 15. GAGs-potentiated inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III - correlation with total charge density.
    Cofrancesco E; Vigo A; Pogliani EM
    Thromb Haemost; 1981 Dec; 46(4):749-51. PubMed ID: 6460339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory evaluation of heparin therapy.
    Phillips JD
    Clin Lab Haematol; 1980; 2(1):53-62. PubMed ID: 7379468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS; Heinick J; Günzel P
    Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOY: [ethyl P-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro.
    Ohno H; Kosaki G; Kambayashi J; Imaoka S; Hirata F
    Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):579-88. PubMed ID: 6449757
    [No Abstract]   [Full Text] [Related]  

  • 19. [Monitoring anticoagulant treatment with the KEM-O-MAT 2HP autoanalyzer].
    Laharrague P; Leleu T; Poignot JL; Cambus JP; Biermé R
    Nouv Rev Fr Hematol (1978); 1983; 25(2):107-12. PubMed ID: 6866753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of prothrombin by a micro-coagulation method.
    Kirchhof B; Schmale S; van de Loo J
    Haemostasis; 1983; 13(1):1-8. PubMed ID: 6840624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.